Robotics in medtech are quickly becoming common place as the number of companies in the market continue to grow. On June 12, seasoned veterans of robotic surgery companies will share their thoughts about the state of surgical robotics technology at MD&M East.

It's no secret that for many years Intuitive Surgical has long dominated the surgical robotics market.

The Sunnyvale, CA-based company’s name has been synonymous with surgical robotics in medtech. But that is rapidly changing.

Johnson & Johnson’s Ethicon subsidiary along with Alphabet’s Verb, have formed a joint venture called Verb that could give Intuitive a run for its money. In addition, Dublin-based Medtronic’s Hugo surgical platform could add even more pressure for Intuitive’s da Vinci platform.

Transenterix, another player in the space, received FDA clearance for the Senhance surgical robot in October 2017. The clearance came after the Triangle Park, NC-based company suffered a series of setbacks. However, the company recovered, and the Senhance was the second surgical robot cleared for abdominal entry since Intuitive received an FDA nod in 2000. 

There has also been some significant M&A activity in the surgical robotics space too. Medtronic acquired Mazor for $1.6 billion. Prior to the acquisition, the two had been working to integrate Medtronic's spine implants, navigation, and intra-operative imaging technology with Mazor's robotic-assisted surgery systems. 

Stryker spent $1.7 billion to boost its efforts in surgical robotics when it picked up Mako. Zimmer Biomet even got on the bandwagon when it acquired Medtech S.A. for $133 million.